CD24 and pancreatic neoplasm: FH535 has also demonstrated anti-CSC activity in pancreatic cancer models, reducing clonogenicity and CD24−/CD44+ marker expression in vitro, as well as inhibiting metastasis and tumor growth in xenograft models [440,441].